Compare Bandwidth Inc (BAND) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bandwidth Inc vs Sanofi SA — how do they compare? Bandwidth Inc trades at $51.42 (market cap $1.66B), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 62.8× Bandwidth Inc's market cap, and Sanofi SA pays a 5.55% dividend while Bandwidth Inc pays none. Which is the better fit depends on your goals.
| BAND | SNY | |
|---|---|---|
Market Cap | $1.66B | $104.30B |
Sector | Technology | Health |
52-Week High | $78.44 | $52.34 |
52-Week Low | $12.82 | $41.33 |
Enterprise Value | $2.04B | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bandwidth (BAND) trades at $52.30, down 0.78% on the day, with strong technical momentum showing bullish moving averages but overbought RSI signals. The company demonstrated solid Q2 2026 performance with EPS of $0.37 beating estimates and 22% revenue growth, driven by AI-driven communications demand and enterprise wins. Analyst sentiment remains overwhelmingly positive with 75% buy ratings and a $75.25 consensus price target representing 44% upside potential.
The outlook appears favorable with accelerating AI adoption and raised 2026 guidance, though valuation remains elevated at 34x EBITDA. Key risks include execution challenges in scaling AI deployments and competitive pressure in cloud communications. Current profitability metrics show improvement but remain thin, requiring sustained growth to justify premium multiples.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bandwidth Inc
Bandwidth is a global communications software company. Its CPaaS platform allows enterprises to embed voice, messaging, and 911 emergency services directly into their software applications via robust APIs.
Read more on BAND →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
